CD19 onCARlytics
B-cell hematological malignancies (e.g., Leukemia, Lymphoma)
Pre-clinicalResearch stage
Key Facts
Indication
B-cell hematological malignancies (e.g., Leukemia, Lymphoma)
Phase
Pre-clinical
Status
Research stage
Company
About Imugene
Imugene is focused on developing next-generation immunotherapies that aim to stimulate the body's immune system to fight cancer. Its core technology platforms include oncolytic virotherapy (CF33), B-cell immunotherapy (HER-Vaxx), and checkpoint inhibitor therapies. The company has multiple candidates in clinical development, primarily targeting gastrointestinal cancers and other solid tumors, and operates through strategic collaborations with leading cancer research institutions.
View full company profile